Browse by all authors Browse By Author ID - Sheila Anne Doggrell

Browse Results (48 results found)

Subscribe to the RSS feed for this result setSubscribe to the RSS feed for this result set

Refine

  Abstract Views File Downloads Thomson Reuters Web of Science Citation Count Scopus Citation Count Altmetric Score
Doggrell, Sheila A. (2001) Alteplase: descendancy in myocardial infarction, ascendancy in stroke. Expert Opinion On Investigational Drugs, 10 11: 2013-2029. doi:10.1517/13543784.10.11.2013 94   2 Cited 4 times in Scopus4 0
Doggrell, Sheila A. (2001) Amiodarone - waxed and waned and waxed again. Expert Opinion on Pharmacotherapy, 2 11: 1877-1890. doi:10.1517/14656566.2.11.1877 72   Cited 23 times in Scopus23 0
Doggrell, Sheila A. (2002) Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease. Expert opinion on Pharmacotherapy, 3 11: 1543-1556. doi:10.1517/14656566.3.11.1543 61   Cited 11 times in Scopus11 0
Doggrell, Sheila A. (2005) A small-molecule lead compound for the treatment of Alzheimer's disease. Expert Opinion On Investigational Drugs, 14 2: 199-201. doi:10.1517/13543784.14.2.199 76   0 Cited 0 times in Scopus0 0
Doggrell, Sheils A. (2005) Berberine - a novel approach to cholesterol lowering. Expert Opinion On Investigational Drugs, 14 5: 683-685. doi:10.1517/13543784.14.5.683 85   25 Cited 27 times in Scopus27 1
Doggrell, Sheila A. (2005) BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert Opinion On Investigational Drugs, 14 1: 89-91. doi:10.1517/13543784.14.1.89 45   28 Cited 29 times in Scopus29 0
Doggrell, Sheila A. (2001) Brain natriuretic peptide: Disease marker or more in cardiovascular medicine?. Drugs of Today, 37 7: 463-476. doi:10.1358/dot.2001.37.7.844189 101   5 0
Doggrell, Sheila A. and Wanstall, Janet C. (2005) Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Canadian Journal of Physiology And Pharmacology, 83 2: 123-130. doi:10.1139/Y04-136 38   24 Cited 30 times in Scopus30 0
Doggrell, Sheila A. (2005) CHARMed - the effects of candesartan in heart failure. Expert Opinion On Pharmacotherapy, 6 3: 513-516. doi:10.1517/14656566.6.3.513 61   0 Cited 2 times in Scopus2 0
Brown, Lindsay. and Doggrell, Sheila A. (1999) Cholesterol, coronary artery disease, statins and consequences. New Zealand Pharmacy, 19 8: 25-27. 43  
Doggrell, Sheila A. (2002) Class benefits of AT1 antagonists in Type 2 diabetes with nephropathy. Expert opinion on Pharmacotheraphy, 3 5: 625-628. doi:10.1517/14656566.3.5.625 46   Cited 5 times in Scopus5 0
Doggrell, Sheila A. (2001) Clinical trials with glycoprotein IIB/IIIA antagonists - No benefit without bleeding?. Drugs of Today, 37 8: 509-531. doi:10.1358/dot.2001.37.8.844169 43   3 0
Doggrell, Sheila A. (2002) Clopidogrel: A CURE in acute coronary syndromes? (A Key Paper Evaluation). Exper Opinion in Pharmacotherapy, 3 3: 351-353. doi:10.1517/14656566.3.3.351 49   Cited 2 times in Scopus2 0
Doggrell, Sheila A. (2005) Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opinion On Pharmacotherapy, 6 1: 75-84. doi:10.1517/14656566.6.1.75 215   23 Cited 31 times in Scopus31 0
Doggrell, Sheila A. and Brown, Lindsay (2000) D-Sotalol: death by the SWORD or deserving of further consideration for clinical use?. Expert Opinion On Investigational Drugs, 9 7: 1625-1634. doi:10.1517/13543784.9.7.1625 91   6 0
Doggrell, Sheila A. (2002) Effects of BDF 9198 on left ventricular contractility in advanced spontaneously hypertensive rats with heart failure. Journal of Pharmacy And Pharmacology, 54 8: 1097-1102. doi:10.1211/002235702320266253 38   0 Cited 0 times in Scopus0 0
Doggrell, Sheila A. and Nand, Vinita (2002) Effects of dofetilide on cardiovascular tissues from normo- and hypertensive rats. Journal of Pharmacy And Pharmacology, 54 5: 707-715. doi:10.1211/0022357021778862 34   0 Cited 1 times in Scopus1 0
Doggrell, Sheila A., Brown, Lindsay and Castaner, J (2002) EMD-57033. Treatment of heart failure, calcium sensitizer. Drugs of The Future, 27 1: 14-20. doi:10.1358/dof.2002.027.01.652651 48   1 Cited 2 times in Scopus2 0
Wanstall, Janet C., Homer, Kerry L. and Doggrell, Sheila A. (2005) Evidence for, and importance of, cGMP-Independent Mechanisms with NO and NO Donors and Blood Vessels and Platelets. Current and Vascular Pharmacology, 3 1: 41-53. doi:10.2174/1570161052773933 29   Cited 50 times in Scopus50 0
Doggrell, Sheila A. (2005) Farnesoid X receptor agonism - a new approach to the treatment of cholesterol gallstone disease. Expert Opinion On Investigational Drugs, 14 4: 535-538. doi:10.1517/13543784.14.4.535 41   1 Cited 1 times in Scopus1 0
Doggrell, Sheila A. (2002) Fondaparinux verses enoxaparin for the prevention of venous thromboembelism. Expert opinion on Pharmacotherapy, 3 4: 455-457. doi:10.1517/14656566.3.4.455 29   Cited 2 times in Scopus2 0
Doggrell, Sheila A. (2002) Functional beta(1)- and beta(2)-adrenoceptors in the left and right atrium of pre-hypertensive rats. Journal of Pharmacy And Pharmacology, 54 10: 1407-1412. doi:10.1211/002235702760345509 38   1 Cited 1 times in Scopus1 0
Doggrell, Sheila A., Wanstall, Janet C. and Gambino, Agatha (1999) Functional effects of 4-aminopyridine (4-AP) on pulmonary and systemic vessels from normoxic control and hypoxic pulmonary hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 360 3: 317-323. doi:10.1007/s002109900064 41   15 Cited 15 times in Scopus15 0
Doggrell, Sheila A. (2005) Inhibitors of cholesteryl ester transfer protein - a step forward in the treatment of coronary artery disease?. Drugs of The Future, 30 1: 45-50. doi:10.1358/dof.2005.030.01.870718 52   0 Cited 1 times in Scopus1 0
Doggrell, Sheila A. (2001) Is bucindolol BEST? (A Key Paper Evaluation). Expert Opinion in Pharmacotherapy, 2 10: 1703-1705. doi:10.1517/14656566.2.10.1703 44   0
Doggrell, S., Field, C., Diwan, V. and Kairuz, T. (2012). Low adherence and understanding of medicines in the older-aged living in rental retirement villages. In: Proceedings of the National Medicines Symposium. National Medicines Symposium, Sydney, Australia, (). 24 - 25 May 2012. 21  
Doggrell, Sheila A. (2002) Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect. Expert opinion on Pharmacotherapy, 3 7: 1011-1013. doi:10.1517/14656566.3.7.1011 44   Cited 9 times in Scopus9 0
Doggrell, Sheila A. (2005) NF-gamma B - a target in the inflammation of bone destruction. Expert Opinion On Therapeutic Targets, 9 1: 191-193. doi:10.1517/14728222.9.1.191 57   1 Cited 1 times in Scopus1 0
Doggrell, Sheila A., del Fresno, M. and Castaner, J. (2002) NPS-2143 - Treatment of osteoporosis - Calcilytic. Drugs of The Future, 27 2: 140-142. doi:10.1358/dof.2002.027.02.656406 84   4 Cited 4 times in Scopus4 0
Doggrell, Sheila A. (2001) Parathyroid hormone (1-34): A major advance in the treatment of osteoporosis?. Expert Opinion Pharmacotherapy, 2 11: 1919-1920. doi:10.1517/14656566.2.11.1919 38   0
Doggrell, Sheila A. (2001) Pharmacotherapy of intermittent claudication. Expert opinion on pharmacotherapy, 2 11: 1725-1736. doi:10.1517/14656566.2.11.1725 54   Cited 9 times in Scopus9 0
Doggrell, Sheila A. and Brown, Lindsay (2002) Present and future pharacotherapy for heart failure. Expert opinion on Pharacotherapy, 3 7: 915-930. doi:10.1517/14656566.3.7.915 41   Cited 19 times in Scopus19 0
Doggrell, Sheila A. (2002) Present and future pharmacotherapy for benign prostatic hyperplasia. Drugs of The Future, 27 10: 973-986. doi:10.1358/dof.2002.027.10.740186 57   5 Cited 8 times in Scopus8 0
Doggrell, Sheila A. (2001) ReoPro rules: results from the 'DoTirofiban and ReoPro give similar efficacy trial' (TARGET) - A Key Paper Evaluation (Topol, Ej et al). Expert Opinion in Pharmacotherapy, 2 9: 1507-1509. doi:10.1517/14656566.2.9.1507 39   Cited 2 times in Scopus2 0
Chen, Ying-Yu and Doggrell, Sheila A. (2002) Responsiveness, affinity constants and beta-adrenoceptor reserves for isoprenaline on aortae from normo-, pre and hypertensive rats. Journal of Pharmacy And Pharmacology, 54 4: 515-522. doi:10.1211/0022357021778790 35   4 Cited 5 times in Scopus5 0
Doggrell, Sheila A. (2002) TACE inhibition: a new approach to treating inflammation. Expert Opinion On Investigational Drugs, 11 7: 1003-1006. doi:10.1517/13543784.11.7.1003 25   25 Cited 25 times in Scopus25 0
Doggrell, Sheila A. (2001) Targets to trials in diabetic complications. Drugs of Today, 37 11: 739-748. doi:10.1358/dot.2001.37.11.844208 33   2 0
Brown, Lindsay., Hoong, Ian and Doggrell, Sheila A. (2000) The heart as a target for oestrogens. Heart, Lung and Circulation, 9 3: 113-125. doi:10.1046/j.1444-2892.2000.009003113.x 38   Cited 10 times in Scopus10 0
Doggrell, Sheila A. (2002) Therapeutic potential of selective superoxide dismutase mimetics. Drugs of The Future, 27 4: 385-390. doi:10.1358/dof.2002.027.04.664560 40   5 Cited 5 times in Scopus5 0
Doggrell, Sheila A. and Brown, Lindsay (2001) The spironolactone renaissance. Expert Opinion On Investigational Drugs, 10 5: 943-954. doi:10.1517/13543784.10.5.943 100   28 Cited 32 times in Scopus32 0
Doggrell, Sheila A. and Brown, Lindsay (2001) The spironolactone renaissance. Expert Opinion on Investigational Drugs, 10 5: 943-954. doi:10.1517/13543784.10.5.943 52   27 Cited 32 times in Scopus32 0
Doggrell, Sheila A. (2002) The therapeutic potential of dopamine modulators on the cardiovascular and renal systems. Expert Opinion On Investigational Drugs, 11 5: 631-644. doi:10.1517/13543784.11.5.631 36   7 Cited 11 times in Scopus11 0
Doggrell, Sheila A. (2002) The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Expert Opinion On Investigational Drugs, 11 11: 1537-1552. doi:10.1517/13543784.11.11.1537 35   9 Cited 11 times in Scopus11 0
Doggrell, Sheila A. and Evans, Suzanne (2003) Treatment of dementia with neurotransmission modulation. Expert Opinion On Investigational Drugs, 12 10: 1633-1654. doi:10.1517/13543784.12.10.1633 53   13 Cited 18 times in Scopus18 0
Doggrell, Sheila A. and Chan, Vincent W. (2001) Using models in cardiovascular research: report on the satellite meeting to the International Congress of Physiological Sciences, Models in Cardiovascular Research. Methods Find Experimental Clinical Pharmacology, 23 8: 457-464. 46  
Doggrell, Sheila A. (2005) Which drug combination for hormone-refractory prostate cancer. Expert Opinion On Pharmacotherapy, 6 4: 667-670. doi:10.1517/14656566.6.4.667 66   1 Cited 1 times in Scopus1 0
Doggrell, Sheila A. and Wanstall, Janet C. (2003) Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders?. Expert Opinion On Investigational Drugs, 12 8: 1429-1432. doi:10.1517/13543784.12.8.1429 41   5 Cited 6 times in Scopus6 0
Doggrell, Sheila A. (2005) Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?. Expert Opinion On Investigational Drugs, 14 3: 339-342. doi:10.1517/13543784.14.3.339 64   7 Cited 12 times in Scopus12 0